Celiac Disease Epidemiology Forecast till 2030

Posted on
by

Celiac Disease Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Celiac Disease Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Celiac Disease (CD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Celiac Disease (CD) also known as coeliac disease/non-tropical sprue or gluten-sensitive enteropathy, is defined as a chronic, multiple-organ small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed people. It is a serious autoimmune disorder where the ingestion of gluten leads to damage in the small intestine; it is not an allergy caused by gluten.

 

Celiac Disease Epidemiology Insights 

  • The total Celiac Disease prevalent population in 7 MM in 2017 was 6,334,993  
  • The maximum number of cases of Celiac Disease in the United States in 2017 was found in the age group of 19–39 years was 241,354

  • Type-Specific Celiac Disease Diagnosed Prevalence in the United States in 2017
    Classical – 178,536
    Non-classical – 343,847
    Sub-clinical- 138,861 

  • The total prevalent population of Celiac Disease in 2017
    Germany – 738,357
    the United Kingdom – 650,676
    Spain – 421,326
    Japan – 65,148

  • The cases of Celiac Disease in the United States in 2017
    • 238,048 – Males
    • 423,196 – Females

 

Celiac Disease Epidemiology Segmentation in 7MM from 2017 to 2030

  • Total Prevalent Population of Celiac Disease
  • Total Diagnosed Prevalent Population of Celiac Disease
  • Gender-specific Diagnosed Prevalent Population of Celiac Disease
  • Type-specific Diagnosed Prevalent Population of Celiac Disease
  • Age-specific distribution of Celiac Disease

Request for sample pages

Table of contents

1. Key Insights

2. Executive Summary of Celiac Disease (CD)

3. Celiac Disease (CD): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Celiac Disease (CD) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Celiac Disease (CD) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Celiac Disease (CD) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Celiac Disease (CD) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Celiac Disease (CD) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Celiac Disease (CD) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Celiac Disease (CD) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Celiac Disease (CD) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Celiac Disease (CD) Treatment and Management

6.2. Celiac Disease (CD) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/